Results 31 to 40 of about 1,988,593 (307)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Journal of Medical Case Reports, 2011
Introduction In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions.
Scheid Christoph, Kochanek Matthias, Nogova Lucia, Rothe Achim, Shimabukuro-Vornhagen Alexander, von Bergwelt-Baildon Michael   +5 more
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +2 more sources

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

Haematologica, 2010
Background Residual chronic myeloid leukemia disease following imatinib treatment has been attributed to the presence of quiescent leukemic stem cells intrinsically resistant to imatinib.
Fabrizio Vianello, Federica Villanova, Veronica Tisato, Stefania Lymperi, Ka-Kei Ho, Ana R. Gomes, David Marin, Dominique Bonnet, Jane Apperley, Eric W.-F. Lam, Francesco Dazzi   +10 more
doaj   +1 more source

Bilateral vision loss as initial presentation of chronic myeloid leukemia in a young adult: A case report and review of the literature

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case of bilateral vision loss as the primary presenting symptom of chronic myeloid leukemia in a young adult. Observations: The 28-year-old male patient presented to clinic with visual acuity of 20/200 in both eyes after several ...
Nathan J. Brown, Erin A. Kaya, Jonathan G. Haymore, Lauren V. Gioia   +3 more
doaj   +1 more source

Chronic Myeloid Leukemia in 2007 [PDF]

Journal of Managed Care Pharmacy, 2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed.CML is a myeloproliferative disorder that affects all lineages of hematopoiesis.
openaire   +3 more sources

A prisoner with chronic myeloid leukemia [PDF]

Bone Marrow Transplantation, 1999
The health care received by prisoners in the area of tissue and organ transplantation is not well discussed or documented. We encountered a prisoner with newly diagnosed chronic myelogenous leukemia who was a candidate for allogeneic bone marrow transplantation and had two HLA-identical siblings who were willing to donate bone marrow.
R, Navari, J, Horner Catt, M, Siegler
openaire   +2 more sources

Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]

, 2010
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio, Beatriz Albella, Agirre, Xabier, Casado, José A., Pujol, MR, Rio, P, Bueren, Juan, Ariana Jacome, Albella Beatriz, Maria Eugenia Alonso-Ferrero, Juan A Bueren, Alonso-Ferrero, Maria Eugenia, María Roser Pujol, Hanenberg, H. (H.), Jacome Ariana, Alonso-Ferrero, ME, Hanenberg, H, Perez, L, Pérez-Fuentes, L. (Laura), Agirre, X, Jacome, A, Juan A. Bueren, Jacome, Ariana, Río Paula, Pujol María Roser, Surrallés Jordi, Prosper-Cardoso, F. (Felipe), Pérez Laura, Maria José Calasanz, Surralles, J. (Jordi), Hanenberg, Helmut, Prosper Felipe, Helmut Hanenberg, Pérez, Laura, Casado, J. (J.A.), Jacome, A. (Ariana), Albella, Beatriz, Bueren, JA, Hanenberg Helmut, Agirre Xabier, Bueren, J.A. (Juan A.), Valeri, A. (Antonio), Rio, P. (Paula), Calasanz-Abinzano, M.J. (Maria Jose), Prosper, F, José A Casado, Laura Pérez, Paula Río, Río, Paula, Antonio Valeri, Casado José A., Valeri Antonio, Jordi Surrallés, Casado, JA, Calasanz Maria José, Felipe Prosper, Surralles, J, José A. Casado, Calasanz, MJ, Albella, B, Albella, B. (B.), Alonso-Ferrero Maria Eugenia, Valeri, A, Alonso-Ferrero, M. (M.E.), Pujol, M.R. (María Roser), Bueren Juan A., Aguirre-Ena, X. (Xabier), Xabier Agirre, Prosper, Felipe, Calasanz, M.J., Pujol Calvet, Maria Roser, Surralles, Jordi   +71 more
core   +2 more sources

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both.
Khadega A. Abuelgasim, Hinna Rehan, Maha Alsubaie, Nasser Al Atwi, Mohammed Al Balwi, Saeed Alshieban, Areej Almughairi   +6 more
doaj   +1 more source

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML

Molecular Therapy: Oncolytics, 2021
Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu, Chuting Li, Rui Su, Zhao Yin, Guiping Huang, Juhua Yang, Zhendong Li, Keda Zhang, Jia Fei   +8 more
doaj   +1 more source

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]

, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core   +1 more source